HRMYMEDIUM SIGNALREGULATORY10-K

HRMY expanded WAKIX approval to include pediatric patients (6+ years) for both EDS and cataplexy in narcolepsy, while advancing multiple late-stage clinical programs beyond the core indication.

The pediatric expansion represents meaningful market expansion for WAKIX, while the company's progression into late-stage trials for idiopathic hypersomnia, Prader-Willi syndrome, and myotonic dystrophy type 1 signals a broader platform approach. The 2022 licensing agreement for next-generation pitolisant products provides additional pipeline optionality, though execution risk remains elevated across multiple concurrent development programs.

Comparing 2026-02-24 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

HRMY's balance sheet strengthened considerably with cash growing to $752.5M (+66.1%) and total assets expanding to $1.3B, while operating cash flow improved substantially to $348.2M. R&D expenses increased 30% to $189.6M, reflecting the company's expanded clinical program investments across multiple indications. The financial position suggests strong cash generation from WAKIX sales while funding diversified development efforts, though capital expenditures declined meaningfully to $310K.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-73.1%
$1.2M→$310K

Capex reduced 73.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
+66.1%
$453.0M→$752.5M

Cash position surged 66.1% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
+58.4%
$219.8M→$348.2M

Operating cash flow surged 58.4% — exceptional cash generation, highest quality earnings signal.

Current Assets
Balance Sheet
+56.6%
$579.3M→$907.0M

Current assets grew 56.6% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
+44%
$175.1M→$252.1M

Current liabilities surged 44% — significant near-term obligations; verify ability to meet short-term debt.

Stockholders Equity
Balance Sheet
+32%
$659.2M→$870.2M

Equity base grew 32% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
+30%
$145.8M→$189.6M

R&D investment increased 30% — signals commitment to future product development, though near-term margin impact.

Total Assets
Balance Sheet
+27.3%
$999.2M→$1.3B

Asset base grew 27.3% — expansion through organic growth, acquisitions, or capital deployment.

Interest Expense
P&L
+26.4%
$18.8M→$23.8M

Interest costs rose 26.4% — monitor debt levels and coverage ratio in rising rate environment.

Inventory
Balance Sheet
-25.6%
$7.2M→$5.4M

Inventory reduced 25.6% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-25
ADDED
As of February 20, 2026, the registrant had 57,840,614 shares of common stock, $0.00001 par value per share, outstanding.
We may not be successful in our efforts to identify other indications for pitolisant beyond EDS and/or cataplexy in adults and pediatric patients six years and older with narcolepsy identify or in-license or acquire, discover, develop or commercialize additional product candidates.
WAKIX has been approved by the FDA for the treatment of EDS and/or cataplexy in adults and pediatric patients six years and older with narcolepsy.
In July 2017, we entered into a License Agreement (as amended, the 2017 LCA ) with Bioprojet Soci t Civile de Recherche ( Bioprojet ) whereby we acquired the exclusive right to commercialize the pharmaceutical compound pitolisant.
Beyond narcolepsy, we have taken a mechanistic-based approach to expanding the reach of pitolisant, advancing late-stage clinical programs exploring pitolisant in idiopathic hypersomnia ( IH ), Prader-Willi syndrome ( PWS ) and myotonic dystrophy type 1 ( DM1 ) and continue to grow our impact in other rare neurological diseases.
+7 more — sign up free →
REMOVED
As of February 21, 2025, the registrant had 57,345,611 shares of common stock, $0.00001 par value per share, outstanding.
We may not be successful in our efforts to identify, in-license or acquire, discover, develop or commercialize additional product candidates, or identify other indications for pitolisant beyond EDS or cataplexy in adult patients with narcolepsy.
WAKIX has been approved by the FDA for the treatment of EDS or cataplexy in adult patients with narcolepsy, and for EDS in children six years of age and older with narcolepsy.
Beyond narcolepsy, we have taken a mechanistic-based approach to expanding the reach of pitolisant, identifying idiopathic hypersomnia ( IH ) as a potential next indication in its lifecycle.
In the fourth quarter of 2024, we submitted a supplemental New Drug Application ( sNDA ) for pitolisant in IH based on a comprehensive evaluation of data from our INTUNE study and additional sources.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →